Drugs / CC-11006
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00458159 | May 2007 → Oct 2008 | myelodysplastic syndrome | Celgene Corporation | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-11006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00458159 ↗ |
| Modality | Small molecule | — CHEMBL4297459 ↗ |
| Route | Oral | “taken once daily, orally.” NCT00458159 ↗ |